Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH) and other liver-related diseases. They generate revenue primarily through research and development partnerships, grants, and potential future product sales. Founded in 2011, Madrigal has made significant strides in the biotechnology sector, particularly with their lead candidate, resmetirom, which is in advanced clinical trials. Understanding their commitment to addressing unmet medical needs and their strategic collaborations is crucial for any potential candidate.

Recent Posts by Madrigal Pharmaceuticals

1-20 of 154